<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945421</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310F201</org_study_id>
    <nct_id>NCT04945421</nct_id>
  </id_info>
  <brief_title>IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC</brief_title>
  <official_title>The Phase Ib/II, Open-label, Multicenter Study of IBI310 (Anti-CTLA4 mAb) in Combination With Sintilimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma That Failed to Prior Anti-PD-1/PD-L1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in&#xD;
      combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma&#xD;
      that failed to prior Anti-PD-1/PD-L1 therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR(Objective response rate)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Investigator evaluated ORR per RECIST V1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR(Duration of Response)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the time from the first documented objective response to the first documented progressive disease or death of any cause, whichever occurs first;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Progress Free Survival)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the time from randomization to the first documented progressive disease or death of any cause, whichever occurs first;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the time from randomization to death of any cause in subjects without receiving any immunotherapy outside the study protocol for first-line treatment of advanced HCC;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR(Disease control rate)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the proportion of patients whose best response is CR, PR, and stable disease (SD) non-CR/non-PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR(Time to progress)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the time from randomization to the first documented and confirmed objective response (CR or PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEAE(Treatment Emergent Adverse Event)/SAE(Serious Adverse Event)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0, 2017) grade;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Quality of life, according to EORTC QLQ-C30</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>According to EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Quality of life, according to EORTC QLQ-H&amp;N35</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>According to EORTC QLQ-H&amp;N35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAs</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The immunogenicity of IBI310 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">121</enrollment>
  <condition>NPC</condition>
  <arm_group>
    <arm_group_label>Sintilimab and IBI310 (single arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group will be treated with either (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
    <arm_group_label>Sintilimab and IBI310 (single arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310</intervention_name>
    <description>(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.</description>
    <arm_group_label>Sintilimab and IBI310 (single arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years;&#xD;
&#xD;
          2. ECOG 0 ~ 1;&#xD;
&#xD;
          3. Histologically/cytologically confirmed R/M NPC;&#xD;
&#xD;
          4. Failed to prior Anti-PD-1 resistance;&#xD;
&#xD;
          5. Adequate organ and bone marrow function;&#xD;
&#xD;
          6. Expected survival ≥12 weeks;&#xD;
&#xD;
          7. Female subjects of childbearing age or male patients whose sex partners are women of&#xD;
             childbearing age should take effective contraceptive measures throughout the treatment&#xD;
             period and within 6 months after the last administration;&#xD;
&#xD;
          8. Subjects who sign the written informed consent form, and can abide by the visits and&#xD;
             related procedures specified in the protocol.&#xD;
&#xD;
          9. At least 1 measurable lesion according to the Response Evaluation Criteria in Solid&#xD;
             Tumors Version 1.1(RECIST V1.1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had tumors other than NPC within the past 5 years.&#xD;
&#xD;
          2. Had allogeneic organ or stem cell transplantation.&#xD;
&#xD;
          3. The presence of uncontrolled life-threatening illness&#xD;
&#xD;
          4. Women of child-bearing potential who are pregnant or breastfeeding because of the&#xD;
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.&#xD;
&#xD;
          5. Patients who have used large doses of glucocorticoids, anti-cancer monoclonal&#xD;
             antibodies, and other immunosuppressive agents within 4 weeks.&#xD;
&#xD;
          6. HIV positive.&#xD;
&#xD;
          7. Patients with significantly lower heart, liver, lung, kidney and bone marrow function.&#xD;
&#xD;
          8. Severe, uncontrolled medical conditions and infections.&#xD;
&#xD;
          9. At the same time using other test drugs or in other clinical trials.&#xD;
&#xD;
         10. Refusal or inability to sign informed consent to participate in the trial.&#xD;
&#xD;
         11. Other treatment contraindications.&#xD;
&#xD;
         12. Emotional disturbance or mental illness, no civil capacity or limited capacity for&#xD;
             civil conduct.&#xD;
&#xD;
         13. Hepatitis B surface antigen (HBsAg) positive and HBVDNA ≥1000cps/ml.&#xD;
&#xD;
         14. Patients with positive HCV antibody test results can only be included in the study&#xD;
             when the polymerase chain reaction of HCV RNA is negative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yang wu</last_name>
    <phone>18117822381</phone>
    <email>yang.wu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
      <phone>13902282893</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

